Abstract: Use of a protein of the SDF-1-family for the manufacturing of a medicament for the improvement of the plasticity and/or regeneration of axons upon their lesion.

Abstract: The invention concerns a nucleic acid molecule which includes a nucleic acid sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide, as well as a host cell which contains this nucleic acid molecule. In addition the invention concerns a polypeptide molecule which functions as chemokine or neuropeptide or contains at least one neuropeptide, as well as fragments thereof which include at least one neuropeptide, and a procedure for the manufacture of the polypeptide molecule or of a fragment thereof. In addition the invention concerns antibodies, demonstration procedures and test-kits as well as pharmaceutical preparations. The purpose on which present invention is based is to make new means available which can be put to use aimed at the diagnosis and/or treatment of diseases which are associated with a defect of the SDF-1 factor or its receptor (CXCR4).

Abstract: A method for the improvement of neuronal regeneration by prevention or inhibition of basal membrane formation induced by a lesion of neuronal tissue.

Abstract: The invention concerns a nucleic acid molecule which includes a nucleic acid sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide, as well as a host cell which contains this nucleic acid molecule. In addition the invention concerns a polypeptide molecule which functions as chemokine or neuropeptide or contains at least one neuropeptide, as well as fragments thereof which include at least one neuropeptide, and a procedure for the manufacture of the polypeptide molecule or of a fragment thereof. In addition the invention concerns antibodies, demonstration procedures and test-kits as well as pharmaceutical preparations.

Abstract: A method for the improvement of neuronal regeneration by prevention or inhibition of basal membrane formation induced by a lesion of neuronal tissue.

Abstract: Oligourethanes containing both anionic and cationic groups may be used as formulating agents for superior aqueous pigment preparations.

Abstract: Oligourethanes containing both anionic and cationic groups may be used as forming agents for superior non-aqueous pigment preparations.

Abstract: Leather treatment agent containing a mixture a) of a carboxylic acidX--COOH Iwherein X represents--[R--CO--Z--(R'--Z).sub.a ].sub.b --CO--R--COOH 1or--R"--(Z--R').sub.c --Z--CO--R--COOH 2and the symbols have the meaning described in more detail in the description, and b) of a compound containing at least one primary, secondary or tertiary amino group, with a molecular weight of 200-20,000, are used in processes for tanning, pretanning, retanning, dyeing or fat liquoring pelts or pretanned leather or fully tanned leather.

Abstract: In the finishing of leather by spray application in an electrostatic field it is possible to use highly concentrated solutions if these solutions are sprayed into a solvent atmosphere in the presence of inert gases. The finishing process utilizes a solvent atmosphere which has a solvent content of 15-90% of the saturation concentration and a residual oxygen content of less than 10% by volume. The finishes contained are immediately stackable. By working with concentrated solutions it is possible to recycle the solvent from the waste air in an economically acceptable manner.

Abstract: Leather treatment agents contain a mixture of(a) 2-98% by weight of an adduct with a molecular weight of 500-50,000 of an alkylene oxide onto an aliphatic or aromatic compound containing one or more hydroxyl groups and(b) 98-2% by weight of a reaction product, containing carboxyl groups or salts thereof, with a molecular weight of 170-20,000 of an aliphatic, cycloaliphatic or aromatic compound containing at least two carboxyl groups or anhydrides thereof and an aliphatic or cycloaliphatic compound containing at least two hydroxyl and/or primary or secondary amino groups and, if appropiate, ether or tertiary amino groups.

Abstract: Aqueous fatliquoring solutions, dispersions or emulsions are made with (a) polyethers having at least two hydroxyl groups and a molecular weight of from 200 to 20,000 and/or (b) polyester containing at least two hydroxyl groups and a molecular weight of from 200 to 20,000 and/or (c) polycarbonates containing at least two hydroxyl groups and a molecular weight of from 200 to 20,000 and/or mixtures thereof. These fatliquoring agents are used to treat tanned leathers until from 0.1 to 20 wt % has been taken up. The thus-treated leather is particularly useful in the production of leather-polyurethane compositions such as shoes without the use of an adhesive.